PubRank

William R Hiatt

Author PubWeight™ 104.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009 5.66
2 Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012 3.39
3 Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011 2.88
4 Exercise training for claudication. N Engl J Med 2002 2.26
5 Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004 2.17
6 Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003 1.93
7 Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006 1.92
8 Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004 1.65
9 Utility and barriers to performance of the ankle-brachial index in primary care practice. Vasc Med 2004 1.57
10 Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003 1.54
11 Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg 2003 1.51
12 A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. J Am Coll Cardiol 2008 1.50
13 Aspirin for prevention of cardiovascular events. BMJ 2008 1.49
14 Inflammation in peripheral artery disease. Circulation 2010 1.47
15 Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Pharmacotherapy 2012 1.46
16 Managing abnormal blood lipids: a collaborative approach. Circulation 2005 1.44
17 Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a veterans affairs population with critical limb ischemia. Catheter Cardiovasc Interv 2009 1.38
18 The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med 2008 1.37
19 Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011 1.35
20 Sharing Data from Cardiovascular Clinical Trials - A Proposal. N Engl J Med 2016 1.34
21 Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med 2015 1.34
22 Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003 1.28
23 Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002 1.26
24 Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011 1.25
25 Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies. Vasc Med 2006 1.24
26 Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007 1.22
27 Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 2002 1.22
28 A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation 2012 1.19
29 Cardiovascular disease mortality in Hispanics and non-Hispanic whites. Am J Epidemiol 2002 1.17
30 Impaired muscle oxygen use at onset of exercise in peripheral arterial disease. J Vasc Surg 2004 1.16
31 Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease. Vasc Med 2007 1.13
32 Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006 1.11
33 Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler Thromb Vasc Biol 2011 1.10
34 Wound healing and functional outcomes after infrainguinal bypass with reversed saphenous vein for critical limb ischemia. J Vasc Surg 2006 1.09
35 Medical therapy in peripheral artery disease. Circulation 2012 1.08
36 Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial disease. Eur J Appl Physiol 2007 1.04
37 Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. J Appl Physiol (1985) 2011 1.03
38 Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion. Vasc Med 2004 1.03
39 Improving the FDA's advisory committee process. J Clin Pharmacol 2011 1.01
40 Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation 2008 1.00
41 Evaluating effects of method of administration on Walking Impairment Questionnaire. J Vasc Surg 2003 0.99
42 A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010 0.99
43 Assessment of functional status and quality of life in claudication. J Vasc Surg 2011 0.98
44 Peripheral arterial disease rehabilitation: a review. J Cardiopulm Rehabil 2003 0.97
45 Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood 2010 0.97
46 Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Vasc Med 2012 0.94
47 The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006 0.93
48 Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design. J Vasc Surg 2008 0.92
49 Fibrates in the treatment of dyslipidemias--time for a reassessment. N Engl J Med 2011 0.92
50 Is revascularization and limb salvage always the best treatment for critical limb ischemia? J Vasc Surg 2003 0.92
51 Pulmonary VO2 dynamics during treadmill and arm exercise in peripheral arterial disease. J Appl Physiol (1985) 2004 0.91
52 Clinical and demographic predictors of exercise capacity in end-stage renal disease. Am J Kidney Dis 2002 0.90
53 Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther 2006 0.90
54 Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes. J Vasc Surg 2007 0.89
55 Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. Am Heart J 2012 0.88
56 Aspirin in primary prevention: can we individualize care? Cardiovasc Diagn Ther 2012 0.88
57 Progression of asymptomatic peripheral artery disease over 1 year. Vasc Med 2012 0.87
58 Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013 0.87
59 TASC II section F on revascularization in PAD. J Endovasc Ther 2007 0.86
60 The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials 2009 0.85
61 Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther 2004 0.83
62 Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function. Vasc Med 2013 0.83
63 Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation 2009 0.82
64 Measurement characteristics of the ankle-brachial index: results from the Action for Health in Diabetes study. Vasc Med 2008 0.81
65 Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. Int J Cardiol 2013 0.81
66 Lack of relationship between gait parameters and physical function in peripheral arterial disease. J Vasc Surg 2006 0.81
67 The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost 2016 0.81
68 Community walking programs for treatment of peripheral artery disease. J Vasc Surg 2013 0.81
69 Prevalence of abnormal ankle-brachial index among individuals with low or intermediate Framingham Risk Scores. J Vasc Interv Radiol 2011 0.80
70 Antiplatelet therapy in peripheral artery disease. Handb Exp Pharmacol 2012 0.80
71 Bridging the quality gap in diabetic hyperlipidemia: a practice-based intervention. Am J Med 2005 0.80
72 A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg 2011 0.80
73 A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication. Vasc Med 2013 0.79
74 The burden of peripheral artery disease and the role of antiplatelet therapy. Postgrad Med 2009 0.79
75 Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease. J Vasc Surg 2013 0.78
76 Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes. Am J Med 2003 0.78
77 Peripheral arterial disease: medical care and prevention of complications. Prev Cardiol 2002 0.78
78 Chinese translation and validation of the Walking Impairment Questionnaire in patients with peripheral artery disease. Vasc Med 2011 0.78
79 Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2013 0.78
80 Atherosclerotic Peripheral Vascular Disease Symposium II: executive summary. Circulation 2008 0.78
81 Can measuring the ankle-brachial index improve public health? J Am Coll Cardiol 2008 0.78
82 Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost 2016 0.78
83 Risk assessment in the patient with established peripheral arterial disease. Vasc Med 2007 0.77
84 Vascular disease: vorapaxar prevents progression of peripheral artery disease. Nat Rev Cardiol 2013 0.77
85 Should an alternate ABI definition be adopted to evaluate risk? J Am Coll Cardiol 2013 0.77
86 Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials 2011 0.76
87 Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia. J Vasc Interv Radiol 2013 0.76
88 Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. JAMA Intern Med 2013 0.76
89 The effects of vascular disease and aging on the regulation of circulating endothelial progenitor cells. Vasc Med 2006 0.75
90 Use of ankle brachial index screening for selecting patients for antiplatelet drug therapy. Pharmacotherapy 2005 0.75
91 A randomized trial of iloprost in patients with intermittent claudication. Vasc Med 2008 0.75
92 Response to McDermott. Circulation 2014 0.75
93 L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vasc Med 2012 0.75
94 The FDA regulatory process for drug and genetic diagnostic test approvals. Clin Transl Sci 2008 0.75
95 Sounding the PAD alarm. GPs can diagnose peripheral artery disease with a simple ankle-and-arm blood pressure test. Health News 2004 0.75
96 Reply: Endovascular-First Treatment of Peripheral Arterial Disease Remains Controversial. J Am Coll Cardiol 2016 0.75
97 Why TASC II? Vasc Med 2007 0.75
98 Treatment of peripheral arterial disease. Clin Cornerstone 2002 0.75
99 Consultations on patients with venous or arterial diseases. Hematology Am Soc Hematol Educ Program 2003 0.75
100 Peripheral arterial disease is not associated with an increased prevalence of intradialytic cramps in patients on maintenance hemodialysis. Am J Nephrol 2002 0.75
101 Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost 2016 0.75
102 An aspirin a day: are we barking up the wrong willow tree? Pharmacotherapy 2010 0.75